Literature DB >> 27379493

Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.

Shuanzeng Wei1,2, Virginia A LiVolsi3, Kathleen T Montone3, Jennifer J D Morrissette4, Zubair W Baloch3.   

Abstract

Medullary thyroid carcinoma (MTC) harbors rearranged during transfection (RET) gene and rarely RAS gene mutations. The knowledge of the type of gene mutation in MTC is important to determine the treatment of the patients and the management of their family members. Targeted next-generation sequencing with a panel of 47 genes was performed in a total of 12 cases of sporadic (9/12) and hereditary MTC (3/12). Two of three hereditary MTCs had RET/C634R mutation, while the other one harbored two RET mutations (L790F and S649L). All the sporadic MTC had RET/M918T mutation except one case with HRAS mutation. Next-generation sequencing (NGS) can provide comprehensive analysis of molecular alterations in MTC in a routine clinical setting, which facilitate the management of the patient and the family members.

Entities:  

Keywords:  HRAS; Medullary thyroid carcinoma; Mutation; RET

Mesh:

Substances:

Year:  2016        PMID: 27379493     DOI: 10.1007/s12022-016-9446-3

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  30 in total

1.  Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.

Authors:  Shuanzeng Wei; David Lieberman; Jennifer J D Morrissette; Zubair W Baloch; David B Roth; Cindy McGrath
Journal:  Cancer Cytopathol       Date:  2015-12-18       Impact factor: 5.284

2.  Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

Authors:  Karin Frank-Raue; Andreas Machens; Christian Scheuba; Bruno Niederle; Henning Dralle; Friedhelm Raue
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-03       Impact factor: 3.478

Review 3.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

4.  Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies.

Authors:  Arne Warth; Roland Penzel; Regine Brandt; Christine Sers; Jürgen R Fischer; Michael Thomas; Felix J F Herth; Manfred Dietel; Peter Schirmacher; Hendrik Bläker
Journal:  Virchows Arch       Date:  2012-03-15       Impact factor: 4.064

5.  The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Authors:  Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

6.  The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.

Authors:  Andrej Zupan; Damjan Glavač
Journal:  Exp Mol Pathol       Date:  2015-08-29       Impact factor: 3.362

7.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

8.  Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

Authors:  A Boichard; L Croux; A Al Ghuzlan; S Broutin; C Dupuy; S Leboulleux; M Schlumberger; J M Bidart; L Lacroix
Journal:  J Clin Endocrinol Metab       Date:  2012-08-03       Impact factor: 5.958

9.  Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.

Authors:  Mario Colombo-Benkmann; Zhenpeng Li; Burkhard Riemann; Karin Hengst; Hermann Herbst; Roger Keuser; Ute Gross; Susanne Rondot; Friedhelm Raue; Norbert Senninger; Brigitte M Pützer; Karin Frank-Raue
Journal:  Eur J Endocrinol       Date:  2008-03-05       Impact factor: 6.664

10.  Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.

Authors:  Hope E Karnes; Eric J Duncavage; Cory T Bernadt
Journal:  Cancer Cytopathol       Date:  2013-11-12       Impact factor: 5.284

View more
  7 in total

Review 1.  Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.

Authors:  Sadegh Rajabi; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

2.  Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.

Authors:  Larissa V Bim; Fábio C P Navarro; Flávia O F Valente; José V Lima-Junior; Rosana Delcelo; Magnus R Dias-da-Silva; Rui M B Maciel; Pedro A F Galante; Janete M Cerutti
Journal:  BMC Med Genomics       Date:  2019-07-09       Impact factor: 3.063

3.  Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.

Authors:  Raffaele Ciampi; Cristina Romei; Teresa Ramone; Alessandro Prete; Alessia Tacito; Virginia Cappagli; Valeria Bottici; David Viola; Liborio Torregrossa; Clara Ugolini; Fulvio Basolo; Rossella Elisei
Journal:  iScience       Date:  2019-09-26

Review 4.  Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.

Authors:  María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

Review 5.  MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives.

Authors:  Francesca Galuppini; Simona Censi; Margherita Moro; Stefano Carraro; Marta Sbaraglia; Maurizio Iacobone; Matteo Fassan; Caterina Mian; Gianmaria Pennelli
Journal:  Cells       Date:  2021-04-20       Impact factor: 6.600

6.  Distribution of RET proto-oncogene variants in children with appendicitis.

Authors:  Jurek Schultz; Ines Freibothe; Michael Haase; Patrick Glatte; Gustavo Barreton; Andreas Ziegler; Heike Görgens; Guido Fitze
Journal:  Mol Genet Genomic Med       Date:  2022-01-03       Impact factor: 2.473

7.  RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.

Authors:  Cristina Romei; Raffaele Ciampi; Francesca Casella; Alessia Tacito; Liborio Torregrossa; Clara Ugolini; Fulvio Basolo; Gabriele Materazzi; Paolo Vitti; Rossella Elisei
Journal:  Oncotarget       Date:  2018-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.